Loading…
Outlook Therapeutics, Inc. is projected to rise to $2.32 by 2027, a +43% move from its current price of $1.62. OTLK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.49 | $1.62 | $1.76 | +0.10% |
| Jul 13 | $1.44 | $1.62 | $1.82 | +0.21% |
| Jul 14 | $1.40 | $1.62 | $1.87 | +0.31% |
| Jul 15 | $1.37 | $1.62 | $1.92 | +0.42% |
| Jul 16 | $1.34 | $1.62 | $1.96 | +0.52% |
| Jul 17 | $1.32 | $1.63 | $2.00 | +0.63% |
| Jul 18 | $1.30 | $1.63 | $2.03 | +0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.30 | $1.63 | $2.03 | +0.73% |
| Week 2 | $1.20 | $1.64 | $2.25 | +1.47% |
| Week 3 | $1.12 | $1.65 | $2.43 | +2.21% |
| Week 4 | $1.06 | $1.66 | $2.60 | +2.96% |
| Week 5 | $1.02 | $1.68 | $2.76 | +3.72% |
| Week 6 | $0.9768 | $1.69 | $2.91 | +4.48% |
| Week 7 | $0.9418 | $1.70 | $3.07 | +5.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, focusing on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Outlook Therapeutics, Inc. (OTLK) is a healthcare stock with a current price of $1.69. The asset trades in the healthcare sector and is identified by the symbol OTLK.
A major floor 87.7% below — a decisive break under it would weaken the trend.
The nearest floor, 56.3% below — buyers have tended to step in here.
The nearest ceiling, 13.3% above — a clean break opens room to run.
A major ceiling 54.4% above — clearing it would confirm fresh momentum.
Key OTLK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OTLK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.56 | Buy | $1.59 | Buy |
| MA 10 | $1.57 | Buy | $1.56 | Buy |
| MA 20 | $1.54 | Buy | $1.44 | Buy |
| MA 50 | $0.8828 | Buy | $1.07 | Buy |
| MA 100 | $0.6058 | Buy | $0.8849 | Buy |
| MA 200 | $0.9191 | Buy | $1.06 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.51 | Neutral |
| Stoch RSI (14) | 8.16 | Buy |
| CCI (20) | 12.58 | Neutral |
| Williams %R (14) | -63.41 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -7.65 | Sell |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 36.59 | Neutral |
| TRIX (15) | 3.45 | Buy |
| Awesome (5,34) | 0.38 | Buy |
| Ultimate (7,14,28) | 51.14 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.65 | Sell |
| ADX (14) | 39.11 | Buy |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is bullish, with RSI14 at 70. The thirty-day range spans from $0.9434 to $3.03.
SMA50 is $0.8287 and SMA200 is $0.9126, with a nearby support at $0.40 and resistance at $1.83.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.198 | $1.62 | $2.46 | 0% | Neutral | |
| $1.68 | $2.32 | $3.45 | +43% | Bullish | |
| $1.83 | $2.68 | $4.25 | +66% | Bullish | |
| $1.97 | $3.04 | $5.06 | +88% | Bullish | |
| $1.81 | $2.93 | $5.08 | +81% | Bullish | |
| $1.95 | $3.29 | $5.92 | +104% | Bullish | |
| $2.53 | $4.47 | $8.28 | +177% | Bullish | |
| $3.22 | $5.92 | $11.27 | +267% | Bullish | |
| $3.87 | $7.40 | $14.45 | +358% | Bullish | |
| $3.67 | $7.29 | $14.56 | +351% | Bullish | |
| $6.37 | $14.16 | $31.08 | +777% | Bullish | |
| $11.38 | $25.29 | $58.17 | +14.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.198 | $1.62 | $2.12 | +0.00% |
| August 2026 | $1.45 | $1.76 | $2.22 | +8.99% |
| September 2026 | $1.45 | $1.78 | $2.29 | +0.90% |
| October 2026 | $1.53 | $1.90 | $2.49 | +6.85% |
| November 2026 | $1.54 | $1.93 | $2.57 | +1.75% |
| December 2026 | $1.44 | $1.83 | $2.46 | -5.29% |
Click any year to see its month-by-month OTLK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, OTLK could reach as high as $2.46, with a base case around $1.62 and support toward $0.198 — roughly 0% from $1.62. A consolidation phase looks the most probable path here.
Expect OTLK to range from $1.68 to $3.45 through 2027. The $2.32 average target implies a +43% move from current prices. That is up +43% on the projected 2026 average. Momentum favours further upside here.
The OTLK price prediction for 2028 points to an average of $2.68 (low $1.83, high $4.25) — a potential gain of +66% on today's $1.62. Buyers look set to stay in control over this stretch.
In 2029, OTLK is projected to trade between $1.97 and $5.06, averaging $3.04 — a potential gain of +88% from today's $1.62. That is up +14% on the projected 2028 average. Momentum favours further upside here.
Outlook Therapeutics, Inc.'s 2030 outlook centres on $2.93, within a $1.81 to $5.08 range. That is -4% versus the projected 2029 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, OTLK could reach as high as $5.92, with a base case around $3.29 and support toward $1.95 — roughly +104% from $1.62. Momentum favours further upside here.
Expect OTLK to range from $2.53 to $8.28 through 2032. The $4.47 average target implies a +177% move from current prices. That is up +36% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The OTLK price prediction for 2033 points to an average of $5.92 (low $3.22, high $11.27) — a potential gain of +267% on today's $1.62. Momentum favours further upside here.
In 2034, OTLK is projected to trade between $3.87 and $14.45, averaging $7.40 — a potential gain of +358% from today's $1.62. That is up +25% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Outlook Therapeutics, Inc.'s 2035 outlook centres on $7.29, within a $3.67 to $14.56 range. That is -2% versus the projected 2034 average. That marks a +351% change versus current levels. Momentum favours further upside here.
By 2040, OTLK could reach as high as $31.08, with a base case around $14.16 and support toward $6.37 — roughly +777% from $1.62. Buyers look set to stay in control over this stretch.
Expect OTLK to range from $11.38 to $58.17 through 2050. The $25.29 average target implies a +14.7x move from current prices. That is up +79% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in OTLK today (≈ 619.195046 OTLK) could be worth
$15,660.38
+$14,660.38 (+1466%) by 2050 · US Dollar
Based on the average projected OTLK price of $25.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OTLKwould be worth at today's price.
$1,000 invested in OTLK on Jul 10, 2025 (≈ 495.04951 OTLK) would be worth
$799.5
-$200.5 (-20.0%) today · 0.80× · US Dollar
Based on a OTLK entry price of $2.02 vs. today's $1.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.45 | $1,113.79 | +11.4% |
| 1 month ago | $0.89 | $1,814.61 | +81.5% |
| 3 months ago | $0.249 | $6,485.94 | +548.6% |
| 6 months ago | $0.574 | $2,813.59 | +181.4% |
| 1 year ago | $2.02 | $799.5 | -20.0% |
| All time (5.0y) ago | $52.2 | $30.94 | -96.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OTLK forecast.
Our base-case forecast reaches $3.20 around 2031.
Implied market cap at $3.20: $475.48M
The multi-year forecast shows bullish sentiment from 2027 onward, with average prices rising substantially over time. Key figures include 2026 min $0.198, avg $1.69, max $2.57 (ROI 0%), 2027 min $1.76, avg $2.42, max $3.61 (ROI 43.2%), 2028 min $1.89, avg $2.77, max $4.39 (ROI 63.7%), 2029 min $2.02, avg $3.12, max $5.20 (ROI 84.5%), 2030 min $1.87, avg $3.02, max $5.24 (ROI 78.6%), 2031 min $1.99, avg $3.36, max $6.04 (ROI 99%), 2032 min $2.59, avg $4.56, max $8.45 (ROI 169.9%), 2033 min $3.30, avg $6.05, max $11.53 (ROI 258.2%), 2034 min $3.92, avg $7.49, max $14.62 (ROI 343.1%), 2035 min $3.71, avg $7.38, max $14.74 (ROI 336.5%), 2040 min $6.40, avg $14.23, max $31.23 (ROI 741.8%), 2050 min $11.30, avg $25.11, max $57.74 (ROI 1385.5%). The sentiment is BULLISH across these years.
The forecast notes an annualized volatility of 200% and presents substantial upside from the baseline price level.
Tap a question to reveal the answer.
2030: min $1.87, avg $3.02, max $5.24; ROI 78.6%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROI reaching 1385.5% by 2050.
Yes. The 2033 max is $11.53, and the 2034 max is $14.62, exceeding $10.
Current price is $1.69 and market cap is $251.11M.
Thirty-day range is $0.9434 to $3.03; sentiment is BULLISH; RSI14 is 70; SMA50 is $0.8287; SMA200 is $0.9126; support is $0.40 and resistance is $1.83.
Outlook Therapeutics, Inc. Community Discussion
0Share your Outlook Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.